Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606476 · ClinicalTrials.gov registry record · Phase 2
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 194
- Enrollment target
NCT00606476: Clinical Trial Phase 2 study, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
NCT00606476 is a Phase 2 study that was terminated before completion, run by JANSSEN Alzheimer Immunotherapy Research & Development. The registered enrollment target is 194 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606476, a Phase 2 study, was terminated before completion, sponsored by JANSSEN Alzheimer Immunotherapy Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 194 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102. All patients enrolled in Study AAB-001-251 will receive infusions of AAB-001 (bapineuzumab), including patients randomized to placebo in Study 201 and 102. Approximately 30 study sites in the US will be involved. Each patient's participation may vary from 3 months up to 84 months depending on the date of enrollment in this study. AAB-001 (bapineuzumab) is a humanized monoclonal antibody, which binds to and potentially clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient.
Interventions
- DRUG Bapineuzumab (AAB-001)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2006-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606476
The ClinicalTrials.gov registry entry for NCT00606476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bapineuzumab (AAB-001) is the first listed.
NCT00606476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00606476 about?
NCT00606476 is a clinical study titled "AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease". This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102. All patients enrolled in Study AAB-001-251 will receive infusions of AAB-001 (bapi...
What is the current status of trial NCT00606476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 194 participants. The study started on 2006-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00606476?
The interventions under investigation include: Bapineuzumab (AAB-001) (DRUG).
Who is sponsoring clinical trial NCT00606476?
This trial is sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.